EVP 1001-1

Drug Profile

EVP 1001-1

Alternative Names: EVP10011; SeeMore

Latest Information Update: 15 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eagle Vision Pharmaceutical Corporation
  • Class Cardiovascular therapies; Contrast media
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Myocardial infarction; Myocardial ischaemia

Most Recent Events

  • 21 Dec 2015 No development reported - Phase-II for Myocardial infarction (Diagnosis) in USA (IV)
  • 21 Dec 2015 No development reported - Phase-II for Myocardial ischaemia (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top